Las Vegas, NV -- (SBWIRE) -- 08/31/2012 -- Beststocksdaily is one of leading U.S. stock update providers to valued investors. Following are the notable volume leaders as reported by http://beststocksdaily.com/
BP Prudhoe Bay Royalty Trust (NYSE:BPT) stock soared 18.08% to $90.65 on an above average volume of 1.85 million shares on no official news. The 52 week trading range for the company is $75.12 - $129.49. The shares of the company declined 18% in the last one year. BPT is a grantor trust. The Trust was formed for the purpose of owning and administering an overriding royalty interest (the Royalty Interest). The Royalty Interest is a non-operational interest in minerals
Can BPT Continue To Move Higher? Get Our Special Report To Get complete technical analysis on CPRX go to http://beststocksdaily.com/p2/index.php?company=BPT
Support.com, Inc. (NASDAQ:SPRT) stock fell 0.96% to $3.11. Zacks upgraded shares of Support.Com from a neutral rating to an outperform rating in a report released yesterday. The company last posted its quarterly earnings results on July 31. The company reported ($0.02) earnings per share for the quarter, beating the analysts’ consensus estimate of ($0.05) by $0.03. The company’s quarterly revenue was up 28.7% on a year-over-year basis. Analysts predict that SPRT will post $-0.08 earnings per share for the current fiscal year.
Can SPRT Recover After The Recent fall? Find Out http://beststocksdaily.com/p2/index.php?company=SPRT?
Visteon Corporation (NYSE:VC) stock gained 8.67% to $46.13 after the shares of VC had its target price lifted by JPMorgan Chase from $35.00 to $50.00 in a report issued today and they currently have a neutral rating on the stock. Additionally, analysts expect that Visteon will post $3.40 EPS for the current fiscal year.
Additionally, the company’s shares increased after after Mando Corp. said it may bid for Visteon’s 70% stake in Halla Climate Control Corp., Mando’s former affiliate.
Get Free Trend Analysis on VC Here http://beststocksdaily.com/p2/index.php?company=VC
Oncolytics Biotech, Inc. (USA) (NASDAQ:ONCY) stock increased 6.03% to $2.80. Equities research analysts at Stifel Nicolaus started coverage on shares of Oncolytics Biotech in a research note issued to investors today and the firm set a “buy” rating and a $6.00 price target on the stock. The company is a development-stage company. The Company have focused the research and development efforts on the development of REOLYSIN, the cancer therapeutic.
Can ONCY Continue To Move Higher? Get Our Special Report To Get complete technical analysis on CPRX go to http://beststocksdaily.com/p2/index.php?company=ONCY
Zale Corporation (NYSE:ZLC) shares climbed 10.62% to $4.79 in the early hour after the company reported a fourth-quarter net loss from continuing operations of $20 million, or $0.61 per share, as compared to a net loss from continuing operations of $33 million, or $1.02 per share, in the year ago period. Revenues increased of 7.9% to $407 million, from $377 million in the same quarter last year. Analysts expected the company to report a loss of $0.84 per share on revenue of $405.38 million for the quarter.
To Get complete technical analysis on ZLC go to http://beststocksdaily.com/p2/index.php?company=ZLC
Beststocksdaily’s team is engaged in providing valuable and updated news information on U.S. stocks on a regular basis. Beststocksdaily’s instant stock news on Major Gainers, small cap penny stocks and various other stocks, guides investors in making the wise stock market investments decision. To Get Instant updates in the inbox, readers are advised to sign up for free at Beststocksdaily.com.
The assembled information disseminated by beststocksdaily.com is for information purposes only, and is neither a solicitation to buy nor an offer to sell securities. beststocksdaily.com does expect that investors will buy and sell securities based on information assembled and presented in beststocksdaily.com. PLEASE always do your own due diligence, and consult your financial advisor.
Copyright © 2005-2013 - SBWire, The Small Business Newswire - All Rights Reserved - Important Disclaimer
Contact Us: 888-4-SBWIRE (US) - 920-593-5640 (International)